DILTIAZEM HYDROCHLORIDE

Post-LOE

diltiazem hydrochloride

Gen Pharmaceuticals

ANDAORALTABLET, EXTENDED RELEASE

Approved

Apr 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DILTIAZEM HYDROCHLORIDE (diltiazem hydrochloride) by Gen Pharmaceuticals is muscle. Approved for hypertension, to lower blood pressure, exercise tolerance in patients with chronic stable angina and 2 more indications. First approved in 2023.

Drug data last refreshed 18h ago

Mechanism of Action

muscle. Hypertension: Diltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. The magnitude of blood pressure reduction is related to the degree of hypertension; thus hypertensive individuals…

Indications (4)

hypertension

Worked on DILTIAZEM HYDROCHLORIDE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.